The evolution of the TOR pathway and its role in cancer. - Test2 - elhamkhani - TriplyDB

The evolution of the TOR pathway and its role in cancer.

The evolution of the TOR pathway and its role in cancer.

http://www.wikidata.org/entity/Q34318188

about

Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting Environmentally induced changes in correlated responses to selection reveal variable pleiotropy across a complex genetic network Regulatory effects of SKAR in interferon α signaling and its role in the generation of type I IFN responses.Pathophysiology of cisplatin-induced acute kidney injury.Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.Intersection of mTOR and STAT signaling in immunity Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo.TORC2 mediates the heat stress response in Drosophila by promoting the formation of stress granules Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells.Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development.Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development.TGF-β/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1α expression.Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer.Critical roles for Rictor/Sin1 complexes in interferon-dependent gene transcription and generation of antiproliferative responses.An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.Balancing act: matching growth with environment by the TOR signalling pathway.Use of mTOR inhibitors in the treatment of malignancies.Gene of the month. AMP kinase (PRKAA1).Targeting novel signaling pathways for resistant acute myeloid leukemia.Role of leptin and leptin receptors in hematological malignancies.Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.Central Regulatory Role for SIN1 in Interferon γ (IFNγ) Signaling and Generation of Biological Responses.Targeting the mTOR Pathway in Leukemia.Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.Arginine dependence of tumor cells: targeting a chink in cancer's armor.

P2860

Q26827387-7F8CFE73-94D7-4C63-A0CC-5452DAB31AC3 Q27007511-696DE6E3-4AD5-4316-8679-B5A55FF9AC4E Q33752594-5EB9B52C-1196-4477-A756-70C5C3B0F043 Q33924663-451CA00A-66A4-4487-9D99-5627BD9354F9 Q34025462-16B45052-3512-478C-B523-ED94D3A26805 Q34073302-B81526DA-AB1B-4245-BD25-A54546A0A11C Q34592659-789F8A21-A324-4FAA-AA73-CAE1E3FD91DA Q34965452-5B67FF6A-331E-457F-A698-E1749AA04E2D Q34978661-1A9B16E2-6DF7-415F-9C26-8D7FD8F1B609 Q35048118-1642EA42-8F1E-49AC-8475-1628D72E0784 Q35217017-F8F18B62-22B7-47C9-8D58-4A1AB984F556 Q35738879-ADBC0659-2B93-468E-8D69-35AF842896A9 Q35878104-254B6839-F72E-4D3A-8C98-75F12E287283 Q36218365-AE67AC11-5378-4A26-9A20-D545AA3864AE Q36413415-64C06526-76BE-4A70-BDBB-27DA04BF1571 Q36525408-485D7DE9-48D4-456B-A4D1-354C3DEA2E1F Q36739319-9A4B87EE-593F-4EAF-B4AC-980D0E0F1DAF Q36901497-8023BF4E-4A00-4211-A63E-AF5E357FA532 Q37099708-5B642368-3281-4F12-9A50-BFB3B7F01634 Q37117628-4C5CEDC4-A8D4-41AF-8130-2E9E00073F80 Q37267205-69AB7349-A0E2-4C86-B8F4-A3D358084902 Q37362875-2F09F73E-364A-4283-93BE-75FB2767FAAF Q37364509-A064AF9A-41B4-474A-865E-B208FA8A9E2A Q37452592-6D1387F4-58DD-475E-A889-695697CE739E Q37476582-689DF56D-51D3-486C-848A-B5255A831B02 Q37577447-644D21A4-9645-48A5-B98A-0F0DE3517C4A Q37622557-07EDF28C-2BC7-40D3-9B5D-C049AB678A77 Q37687374-F1D4EB00-CE61-474C-A373-E11F46CB64AE Q38094782-03EE88A2-ACC2-4DE7-A43C-7403D2C2CCC2 Q38190942-DFD5AA1F-BD89-4E2E-976B-349A9B818C45 Q38199196-DECE38F5-A968-469F-A53C-9804DCEB9981 Q38217467-C446DC1C-F285-402E-A337-1CA4B46A13A4 Q38297507-E1F11359-9FDA-45E4-8F9D-2A33942DD161 Q38298310-22381456-CCB6-43E8-B1F8-3A26A52B64EA Q38514906-149C0677-0ADF-4F83-A0B5-B260E170A84B Q38678966-6CF92E1E-17BE-4499-B3C6-60B75D59EE09 Q38717418-A47AE333-D8F3-4886-B0B2-FAB3B449E970 Q38790630-CC6E09BF-4192-4004-997C-051CFD09850A Q38807880-3D7EEDD4-77A2-424E-9FC0-6F26CCFE2BB0 Q38816145-20847301-E3EC-4E41-9B7D-8DCF67A43F50

P2860

The evolution of the TOR pathway and its role in cancer.

http://www.wikidata.org/entity/Q34318188

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The evolution of the TOR pathway and its role in cancer.

@ast

The evolution of the TOR pathway and its role in cancer.

@en

The evolution of the TOR pathway and its role in cancer.

@nl

type

label

The evolution of the TOR pathway and its role in cancer.

@ast

The evolution of the TOR pathway and its role in cancer.

@en

The evolution of the TOR pathway and its role in cancer.

@nl

prefLabel

The evolution of the TOR pathway and its role in cancer.

@ast

The evolution of the TOR pathway and its role in cancer.

@en

The evolution of the TOR pathway and its role in cancer.

@nl

P1433

Q34318188-F98AD121-9086-495F-B3F1-C1042D5A9BB6

P1476

Q34318188-D5044249-0E14-4731-8A49-75CE048473B4

P2093

Q34318188-0150AE12-9895-4C30-99D3-2665A872D607

Q34318188-52226A15-583D-419A-9F49-23895B45B0D4

P2860

Q34318188-0016C7D6-9E9F-480B-AF99-B1285AFB945C

Q34318188-010C9FC1-6104-42D7-8A44-2AC27252315A

Q34318188-02CFD42C-AF4F-4D56-A3F9-79FAACFA8AB7

Q34318188-02F729F4-C18A-49CF-A08F-C6DAF4B78829

Q34318188-044F17D2-43FB-4806-A058-9199DA9D823E

Q34318188-04E5CB2A-EECE-4E53-959B-132E7E460201

Q34318188-05422A68-5953-4303-9AB6-B62ECB765024

Q34318188-067647F6-DE53-4DBF-BD0C-3F52DBFD2698

Q34318188-08E29137-0D45-49B7-A2A1-4881299BF267

Q34318188-09B80017-BEAD-4F4F-8700-D44D59F62D4E

P2888

Q34318188-18BC8BDF-F2E9-4BAA-BC2A-3D4323F28954

P304

Q34318188-A5FBC400-612E-42DD-A127-6201A8F8F760

P31

Q34318188-ADC89F34-8862-40AF-BECF-92568D38BA94

P356

Q34318188-0B8A53FE-A9D8-4952-A040-B1107568C2F8

P407

Q34318188-5BD36F87-18B2-4323-B5F4-5E313E1B6EED

P433

Q34318188-104C455C-6B6A-44EF-A909-553123BF0961

P478

Q34318188-31CB9CAC-CD18-4990-98A1-DE0CBC906001

P577

Q34318188-A7C89F1E-73E6-4D94-AE53-8A24CCED7E18

P6179

Q34318188-A50C33D3-E0A3-4E21-B885-1C352FACB8F3

P698

Q34318188-FD692A52-509A-449B-B252-17C8DC0D2C5D

P356

P1433

P1476

The evolution of the TOR pathway and its role in cancer.

@en

P2093

E M Beauchamp

http://www.w3.org/2001/XMLSchema#string

L C Platanias

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

Large-scale characterization of HeLa cell nuclear phosphoproteins

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

The crosstalk of mTOR/S6K1 and Hedgehog pathways

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

P2888

P304

3923-3932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2012.567

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026766661

http://www.w3.org/2001/XMLSchema#string

P698

23246968

http://www.w3.org/2001/XMLSchema#string